Grade My Investments
HomeFree Stock Grades › SEPN

Septerna Inc (SEPN) Stock Grade

SEPN · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.2B
P/E Ratio
Revenue Growth (YoY)
+4174.5%
Net Margin
-106.4%
Return on Equity
Dividend Yield
None

About Septerna Inc's fundamentals

Septerna Inc is a biotechnology company with a market capitalization of $1.2 billion that reported exceptional revenue growth of 4,174.5% year-over-year, indicating rapid commercialization or scale-up of its business. However, the company is currently unprofitable, with a net margin of -106.4%, meaning it lost $1.06 for every dollar of revenue generated in its latest annual period. Despite the accounting losses, Septerna generated positive free cash flow, suggesting that while the company is not yet profitable, its operations are producing cash. The company does not pay a dividend.

Track SEPN free — no credit card required. Live grade + monthly AI report →